Long-term follow-up of essential thrombocythemia in young adults: Treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients

Haematologica

Volumn 95, Issue 6, 2010, Pages 1038-1040

  Palandri, Francesca ^a   Polverelli, Nicola ^a   Ottaviani, Emanuela ^a   Castagnetti, Fausto ^a   Baccarani, Michele ^a   Vianelli, Nicola ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

ET; Myelofibrosis; Young adults

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; ANTITHROMBOCYTIC AGENT; BUSULFAN; HYDROXYUREA; JANUS KINASE 2; PHENYLALANINE; PIPOBROMAN; VALINE;

ADULT; AGE DISTRIBUTION; BLEEDING DISORDER; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HETEROZYGOSITY; HUMAN; LETTER; LEUKOCYTE COUNT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MUTATIONAL ANALYSIS; PREGNANCY OUTCOME; RETROSPECTIVE STUDY; SEX DIFFERENCE; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT PLANNING;

ADOLESCENT; ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT, NEWBORN; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY OUTCOME; THROMBOCYTHEMIA, ESSENTIAL; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953188086     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.019190     Document Type: Letter

References (12)

1. Millard FE, Hunter CS, Anderson M, Edelman MJ, Kosty MP, Luiken GA, et al. Clinical manifestations of essential thrombo-cythemia in young adults. Am J Hematol 1990;33:27-31.
2. Randi ML, Rossi C, Fabris F, Girolami A. Essential thrombo-cythemia in young adults: major thrombotic complications and complications during pregnancy-a follow-up study in 68 patients. Clin Appl Thromb Hemost 2000;6(1):31-5.
3. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood. 2003;101(9):3749.
4. Storen A, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood. 2001;97(4):863-866
5. Passamonti F, Rumi E, Malabarba L, Arcaini L, Orlandi E, Brusamolino E, et al. Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. Ann Hematol 2004 Aug;83(8):495-497
6. Alvarez-Larrán A, Cervantes F, Bellosillo B, Giralt M, Juliá A, Hernández-Boluda JC, et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 2007;21(6):1218-23.
7. Melillo L, Tieghi A, Candoni A, Radaelli F, Ciancia R, Specchia G, et al. Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry. Am J Hematol 2009 Jul 16. [Epub ahead of print]
8. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombo- cythemia: a final report on diagnostic criteria, survival and leukemic transition by treatment. Semin Hematol 1997;34:29-39.
9. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-7.
10. Palandri F, Ottaviani E, Salmi F, Catani L, Polverelli N, Fiacchini M, et al. JAK2V617F mutation in essential thrombocythemia: correlation with clinical characteristics, responce to therapy and long-term out come in a cohort of 275 patients. Leuk Lymphoma 2009;50(2):247-53.
11. Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica. 2007;92(1):135-6.
12. Palandri F, Catani L, Testoni N, Ottaviani E, Polverelli N, Fiacchini M, et al. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreduc- tive therapy. Am J Hematol. 2009;84(4):215-20.